BIOGEN INC (IDP.DE) Stock Fundamental Analysis
FRA:IDP - Deutsche Boerse Ag - US09062X1037 - Common Stock - Currency: EUR
IDP gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 72 industry peers in the Biotechnology industry. IDP scores excellent on profitability, but there are some minor concerns on its financial health. IDP has a bad growth rate and is valued cheaply. These ratings could make IDP a good candidate for value investing.
1. Profitability
1.1 Basic Checks
In the past year IDP was profitable.
IDP had a positive operating cash flow in the past year.
IDP had positive earnings in each of the past 5 years.
In the past 5 years IDP always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 5.70%, IDP belongs to the top of the industry, outperforming 92.19% of the companies in the same industry.
IDP has a better Return On Equity (9.87%) than 87.50% of its industry peers.
With an excellent Return On Invested Capital value of 9.36%, IDP belongs to the best of the industry, outperforming 90.63% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for IDP is in line with the industry average of 10.31%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.7% | ||
| ROE | 9.87% | ||
| ROIC | 9.36% |
ROA(3y)7.75%
ROA(5y)12.23%
ROE(3y)14.96%
ROE(5y)25.28%
ROIC(3y)12.12%
ROIC(5y)17.18%
1.3 Margins
IDP's Profit Margin of 16.81% is amongst the best of the industry. IDP outperforms 92.19% of its industry peers.
IDP's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 25.92%, IDP belongs to the top of the industry, outperforming 93.75% of the companies in the same industry.
In the last couple of years the Operating Margin of IDP has declined.
IDP has a better Gross Margin (75.59%) than 73.44% of its industry peers.
IDP's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.92% | ||
| PM (TTM) | 16.81% | ||
| GM | 75.59% |
OM growth 3Y-15.78%
OM growth 5Y-14.65%
PM growth 3Y-26.52%
PM growth 5Y-18.55%
GM growth 3Y-4.45%
GM growth 5Y-2.68%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so IDP is still creating some value.
The number of shares outstanding for IDP has been increased compared to 1 year ago.
The number of shares outstanding for IDP has been reduced compared to 5 years ago.
Compared to 1 year ago, IDP has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.67 indicates that IDP is not a great score, but indicates only limited risk for bankruptcy at the moment.
IDP's Altman-Z score of 2.67 is fine compared to the rest of the industry. IDP outperforms 75.00% of its industry peers.
The Debt to FCF ratio of IDP is 3.56, which is a good value as it means it would take IDP, 3.56 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of IDP (3.56) is better than 89.06% of its industry peers.
IDP has a Debt/Equity ratio of 0.28. This is a healthy value indicating a solid balance between debt and equity.
IDP's Debt to Equity ratio of 0.28 is in line compared to the rest of the industry. IDP outperforms 54.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 3.56 | ||
| Altman-Z | 2.67 |
ROIC/WACC0.92
WACC10.2%
2.3 Liquidity
IDP has a Current Ratio of 1.26. This is a normal value and indicates that IDP is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of IDP (1.26) is worse than 71.88% of its industry peers.
A Quick Ratio of 0.80 indicates that IDP may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.80, IDP is doing worse than 78.13% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.26 | ||
| Quick Ratio | 0.8 |
3. Growth
3.1 Past
IDP shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.16%.
IDP shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -10.49% yearly.
The Revenue has decreased by -3.86% in the past year.
IDP shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -6.07% yearly.
EPS 1Y (TTM)3.16%
EPS 3Y-22.83%
EPS 5Y-10.49%
EPS Q2Q%-6.42%
Revenue 1Y (TTM)-3.86%
Revenue growth 3Y-9.9%
Revenue growth 5Y-6.07%
Sales Q2Q%-2.54%
3.2 Future
IDP is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.69% yearly.
IDP is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.37% yearly.
EPS Next Y10.8%
EPS Next 2Y5.95%
EPS Next 3Y5.97%
EPS Next 5Y5.69%
Revenue Next Year-2.86%
Revenue Next 2Y-2.21%
Revenue Next 3Y-0.93%
Revenue Next 5Y0.37%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 8.75 indicates a reasonable valuation of IDP.
IDP's Price/Earnings ratio is rather cheap when compared to the industry. IDP is cheaper than 96.88% of the companies in the same industry.
IDP's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.47.
IDP is valuated reasonably with a Price/Forward Earnings ratio of 8.44.
Based on the Price/Forward Earnings ratio, IDP is valued cheaper than 93.75% of the companies in the same industry.
IDP is valuated cheaply when we compare the Price/Forward Earnings ratio to 92.74, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.75 | ||
| Fwd PE | 8.44 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IDP is valued cheaper than 90.63% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, IDP is valued cheaply inside the industry as 93.75% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.78 | ||
| EV/EBITDA | 8.15 |
4.3 Compensation for Growth
IDP's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of IDP may justify a higher PE ratio.
PEG (NY)0.81
PEG (5Y)N/A
EPS Next 2Y5.95%
EPS Next 3Y5.97%
5. Dividend
5.1 Amount
No dividends for IDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIOGEN INC
FRA:IDP (2/4/2025, 7:00:00 PM)
138.3
-0.8 (-0.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners92.13%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap20.15B
Analysts75.24
Price Target221.99 (60.51%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.05%
Min EPS beat(2)5.5%
Max EPS beat(2)28.61%
EPS beat(4)4
Avg EPS beat(4)10.01%
Min EPS beat(4)1.62%
Max EPS beat(4)28.61%
EPS beat(8)8
Avg EPS beat(8)8.49%
EPS beat(12)10
Avg EPS beat(12)8.67%
EPS beat(16)13
Avg EPS beat(16)8.57%
Revenue beat(2)1
Avg Revenue beat(2)0.4%
Min Revenue beat(2)-0.68%
Max Revenue beat(2)1.48%
Revenue beat(4)1
Avg Revenue beat(4)-1.79%
Min Revenue beat(4)-5.08%
Max Revenue beat(4)1.48%
Revenue beat(8)5
Avg Revenue beat(8)0.42%
Revenue beat(12)7
Avg Revenue beat(12)0.61%
Revenue beat(16)9
Avg Revenue beat(16)0.82%
PT rev (1m)-5.24%
PT rev (3m)-10.29%
EPS NQ rev (1m)-0.17%
EPS NQ rev (3m)-14.8%
EPS NY rev (1m)-0.03%
EPS NY rev (3m)0.44%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)0.74%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)0.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.75 | ||
| Fwd PE | 8.44 | ||
| P/S | 2.17 | ||
| P/FCF | 11.78 | ||
| P/OCF | 9.79 | ||
| P/B | 1.27 | ||
| P/tB | 308.11 | ||
| EV/EBITDA | 8.15 |
EPS(TTM)15.8
EY11.42%
EPS(NY)16.38
Fwd EY11.84%
FCF(TTM)11.74
FCFY8.49%
OCF(TTM)14.12
OCFY10.21%
SpS63.79
BVpS108.62
TBVpS0.45
PEG (NY)0.81
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.7% | ||
| ROE | 9.87% | ||
| ROCE | 10.88% | ||
| ROIC | 9.36% | ||
| ROICexc | 10.11% | ||
| ROICexgc | 43.72% | ||
| OM | 25.92% | ||
| PM (TTM) | 16.81% | ||
| GM | 75.59% | ||
| FCFM | 18.41% |
ROA(3y)7.75%
ROA(5y)12.23%
ROE(3y)14.96%
ROE(5y)25.28%
ROIC(3y)12.12%
ROIC(5y)17.18%
ROICexc(3y)14.77%
ROICexc(5y)20.81%
ROICexgc(3y)31.37%
ROICexgc(5y)43%
ROCE(3y)14.1%
ROCE(5y)19.98%
ROICexcg growth 3Y-19.11%
ROICexcg growth 5Y-16.33%
ROICexc growth 3Y-29.06%
ROICexc growth 5Y-22.85%
OM growth 3Y-15.78%
OM growth 5Y-14.65%
PM growth 3Y-26.52%
PM growth 5Y-18.55%
GM growth 3Y-4.45%
GM growth 5Y-2.68%
F-Score6
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 3.56 | ||
| Debt/EBITDA | 1.46 | ||
| Cap/Depr | 57% | ||
| Cap/Sales | 3.73% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 68.18% | ||
| Profit Quality | 109.49% | ||
| Current Ratio | 1.26 | ||
| Quick Ratio | 0.8 | ||
| Altman-Z | 2.67 |
F-Score6
WACC10.2%
ROIC/WACC0.92
Cap/Depr(3y)56.77%
Cap/Depr(5y)77.88%
Cap/Sales(3y)2.75%
Cap/Sales(5y)3.4%
Profit Quality(3y)119.62%
Profit Quality(5y)111.92%
High Growth Momentum
Growth
EPS 1Y (TTM)3.16%
EPS 3Y-22.83%
EPS 5Y-10.49%
EPS Q2Q%-6.42%
EPS Next Y10.8%
EPS Next 2Y5.95%
EPS Next 3Y5.97%
EPS Next 5Y5.69%
Revenue 1Y (TTM)-3.86%
Revenue growth 3Y-9.9%
Revenue growth 5Y-6.07%
Sales Q2Q%-2.54%
Revenue Next Year-2.86%
Revenue Next 2Y-2.21%
Revenue Next 3Y-0.93%
Revenue Next 5Y0.37%
EBIT growth 1Y3.07%
EBIT growth 3Y-24.11%
EBIT growth 5Y-19.83%
EBIT Next Year37.69%
EBIT Next 3Y12.79%
EBIT Next 5Y11.67%
FCF growth 1Y-18.63%
FCF growth 3Y-30.48%
FCF growth 5Y-25.27%
OCF growth 1Y-11.28%
OCF growth 3Y-28.48%
OCF growth 5Y-24.21%